BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients
Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
---|---|
Data(s) |
20/10/2012
20/10/2012
2011
|
Resumo |
Tumor necrosis factor-related apoptosis-inducing ligand-TNFSF10 (TRAIL), a member of the TNF-alpha family and a death receptor ligand, was shown to selectively kill tumor cells. Not surprisingly, TRAIL is downregulated in a variety of tumor cells, including BCR-ABL-positive leukemia. Although we know much about the molecular basis of TRAIL-mediated cell killing, the mechanism responsible for TRAIL inhibition in tumors remains elusive because (a) TRAIL can be regulated by retinoic acid (RA); (b) the tumor antigen preferentially expressed antigen of melanoma (PRAME) was shown to inhibit transcription of RA receptor target genes through the polycomb protein, enhancer of zeste homolog 2 (EZH2); and (c) we have found that TRAIL is inversely correlated with BCR-ABL in chronic myeloid leukemia (CML) patients. Thus, we decided to investigate the association of PRAME, EZH2 and TRAIL in BCR-ABL-positive leukemia. Here, we demonstrate that PRAME, but not EZH2, is upregulated in BCR-ABL cells and is associated with the progression of disease in CML patients. There is a positive correlation between PRAME and BCR-ABL and an inverse correlation between PRAME and TRAIL in these patients. Importantly, knocking down PRAME or EZH2 by RNA interference in a BCR-ABL-positive cell line restores TRAIL expression. Moreover, there is an enrichment of EZH2 binding on the promoter region of TRAIL in a CML cell line. This binding is lost after PRAME knockdown. Finally, knocking down PRAME or EZH2, and consequently induction of TRAIL expression, enhances Imatinib sensibility. Taken together, our data reveal a novel regulatory mechanism responsible for lowering TRAIL expression and provide the basis of alternative targets for combined therapeutic strategies for CML. Oncogene (2011) 30, 223-233; doi:10.1038/onc.2010.409; published online 13 September 2010 Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP-Brazil) Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) FAPESP Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) Brazilian Research Council (CNPq-Brazil) Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) |
Identificador |
ONCOGENE, v.30, n.2, p.223-233, 2011 0950-9232 http://producao.usp.br/handle/BDPI/28251 10.1038/onc.2010.409 |
Idioma(s) |
eng |
Publicador |
NATURE PUBLISHING GROUP |
Relação |
Oncogene |
Direitos |
restrictedAccess Copyright NATURE PUBLISHING GROUP |
Palavras-Chave | #PRAME #TRAIL #TNFSF10 #EZH2 #CML #BCR-ABL #APOPTOSIS-INDUCING LIGAND #CHRONIC MYELOID-LEUKEMIA #GENE-EXPRESSION PROFILES #DOWN-REGULATION #IN-VIVO #DEFICIENT MICE #ANTIGEN PRAME #TNF-FAMILY #CELLS #DEATH #Biochemistry & Molecular Biology #Oncology #Cell Biology #Genetics & Heredity |
Tipo |
article original article publishedVersion |